Trial Profile
Safety and efficacy of palonosetron and aprepitant with dexamethasone for prevention of nausea and vomiting in patients with multiple myeloma undergoing autologous transplantation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 15 May 2017 New trial record
- 01 Apr 2017 Results published in the International Journal of Hematology